190 related articles for article (PubMed ID: 28806963)
1. Effectiveness outcomes and health related quality of life impact of disease progression in patients with advanced nonsquamous NSCLC treated in real-world community oncology settings: results from a prospective medical record registry study.
Walker MS; Wong W; Ravelo A; Miller PJE; Schwartzberg LS
Health Qual Life Outcomes; 2017 Aug; 15(1):160. PubMed ID: 28806963
[TBL] [Abstract][Full Text] [Related]
2. Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non-small-cell Lung Cancer in China.
Li X; Abbas M; Li Y; Teng Y; Fang Y; Yu S; Wen Y; Wang L; Shi M
Clin Ther; 2019 Mar; 41(3):518-529. PubMed ID: 30846285
[TBL] [Abstract][Full Text] [Related]
3. Treatment Patterns and Overall Survival Associated with First-Line Systemic Therapy for Patients with Advanced Non-Small Cell Lung Cancer.
Spence MM; Hui RL; Chang JT; Schottinger JE; Millares M; Rashid N
J Manag Care Spec Pharm; 2017 Feb; 23(2):195-205. PubMed ID: 28125366
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis.
Kang EJ; Min KH; Hur GY; Lee SY; Shim JJ; Kang KH; Oh SC; Seo JH; Kim JS
Chemotherapy; 2016; 61(1):41-50. PubMed ID: 26517706
[TBL] [Abstract][Full Text] [Related]
5. An Open-Label Phase II Trial of Bevacizumab plus Docetaxel and Gemcitabine in Advanced, Previously Untreated Nonsquamous Non-Small Cell Lung Cancer.
Patil PD; Shapiro M; Hashemi Sadraei N; Pennell NA
Oncologist; 2019 Apr; 24(4):457-e126. PubMed ID: 30602615
[TBL] [Abstract][Full Text] [Related]
6. Real-life effectiveness of first-line anticancer treatments in stage IIIB/IV NSCLC patients: Data from the Czech TULUNG Registry.
Brat K; Bratova M; Skrickova J; Barinova M; Hurdalkova K; Pesek M; Havel L; Koubkova L; Hrnciarik M; Krejci J; Fischer O; Zemanova M; Coupkova H; Svaton M
Thorac Cancer; 2020 Nov; 11(11):3346-3356. PubMed ID: 33016001
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab in combination with different platinum-based doublets in the first-line treatment for advanced nonsquamous non-small-cell lung cancer: A network meta-analysis.
Zhao S; Gao F; Zhang Y; Zhang Z; Zhang L
Int J Cancer; 2018 Apr; 142(8):1676-1688. PubMed ID: 29171009
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient setting.
Shah M; Winfree KB; Peterson P; Gruschkus SK; Eaddy M; Green MR
Lung Cancer; 2013 Oct; 82(1):121-7. PubMed ID: 23973203
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial.
Takeda M; Yamanaka T; Seto T; Hayashi H; Azuma K; Okada M; Sugawara S; Daga H; Hirashima T; Yonesaka K; Urata Y; Murakami H; Saito H; Kubo A; Sawa T; Miyahara E; Nogami N; Nakagawa K; Nakanishi Y; Okamoto I
Cancer; 2016 Apr; 122(7):1050-9. PubMed ID: 26828788
[TBL] [Abstract][Full Text] [Related]
10. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
11. Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial.
Barlesi F; Scherpereel A; Gorbunova V; Gervais R; Vikström A; Chouaid C; Chella A; Kim JH; Ahn MJ; Reck M; Pazzola A; Kim HT; Aerts JG; Morando C; Loundou A; Groen HJ; Rittmeyer A
Ann Oncol; 2014 May; 25(5):1044-52. PubMed ID: 24585722
[TBL] [Abstract][Full Text] [Related]
12. Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study.
Moro-Sibilot D; Smit E; de Castro Carpeño J; Lesniewski-Kmak K; Aerts J; Villatoro R; Kraaij K; Nacerddine K; Dyachkova Y; Smith KT; Taipale K; Girvan AC; Visseren-Grul C; Schnabel PA
Lung Cancer; 2015 May; 88(2):215-22. PubMed ID: 25748103
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study.
Zhang J; Wu D; Zhang Z; Long J; Tian G; Wang Y; Ma X; Chen X; Han J; Hu W; Dai L; Nie J; Fang J
Technol Cancer Res Treat; 2021; 20():15330338211039676. PubMed ID: 34821175
[No Abstract] [Full Text] [Related]
14. Treatment with or without bevacizumab as a first-line and maintenance therapy for advanced non-squamous non-small cell lung cancer: A retrospective study.
Jun N; Hanping W; Xiaoyan S; Yan X; Mengzhao W; Xiaotong Z; Li Z
Thorac Cancer; 2020 Jul; 11(7):1869-1875. PubMed ID: 32406994
[TBL] [Abstract][Full Text] [Related]
15. Comparative Effectiveness of Carboplatin/Pemetrexed With Versus Without Bevacizumab for Advanced Nonsquamous Non-Small Cell Lung Cancer.
Bagley SJ; Talento S; Mitra N; Meropol NJ; Cohen RB; Langer CJ; Vachani A
J Natl Compr Canc Netw; 2019 May; 17(5):469-477. PubMed ID: 31085759
[TBL] [Abstract][Full Text] [Related]
16. Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study.
Belani CP; Brodowicz T; Ciuleanu TE; Krzakowski M; Yang SH; Franke F; Cucevic B; Madhavan J; Santoro A; Ramlau R; Liepa AM; Visseren-Grul C; Peterson P; John WJ; Zielinski CC
Lancet Oncol; 2012 Mar; 13(3):292-9. PubMed ID: 22336221
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab/pemetrexed alone for stage IIIB/IV nonsquamous non-small cell lung cancer: A meta-analysis of randomized controlled trials.
Liu M; Luo N; Fang Z; Liu Q; Yi F; Wei Y; Zhang X; Zhang W
J Clin Pharm Ther; 2022 Feb; 47(2):157-167. PubMed ID: 34617297
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer.
Spigel DR; Hainsworth JD; Shipley DL; Ervin TJ; Kohler PC; Lubiner ET; Peyton JD; Waterhouse DM; Burris HA; Greco FA
J Thorac Oncol; 2012 Jan; 7(1):196-202. PubMed ID: 21900836
[TBL] [Abstract][Full Text] [Related]
19. [A randomized, controlled, multicenter clinical trial comparing pemetrexed/cisplatin and gemcitabine/cisplatin as first-line treatment for advanced nonsquamous non-small cell lung cancer].
Huang Y; Liu Y; Zhou J; Xu N; Li B; Wu G; Fang J; Li K; Liu X; Liu W; Lu Y; Wang M; Liu W; Liang H; Zhang Y; Huang C; Wang S; Wang Y; Yu S; Chang J; Wang Z; Hu Z; Zhang L
Zhongguo Fei Ai Za Zhi; 2012 Oct; 15(10):576-82. PubMed ID: 23075681
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab treatment to progression after chemotherapy: outcomes from a U.S. community practice network.
Nadler E; Yu E; Ravelo A; Sing A; Forsyth M; Gruschkus S
Oncologist; 2011; 16(4):486-96. PubMed ID: 21441299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]